Expression microarray analysis of papillary thyroid carcinoma and benign thyroid tissue: Emphasis on the follicular variant and potential markers of malignancy

Virchows Archiv

Volumn 450, Issue 3, 2007, Pages 249-260

  Finn, S P ^a   Smyth, P ^a   Cahill, S ^a   Streck, C ^c   O'Regan, E M ^a   Flavin, R ^a   Sherlock, J ^c   Howells, D ^c   Henfrey, R ^c   Cullen, M ^b   Toner, M ^a   Timon, C ^b   O'Leary, J J ^a   Sheils, O M ^a,b  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

^c APPLIED BIOSYSTEMS   (United States)

Author keywords

Biomarker; Follicular variant; Microarray; Papillary thyroid carcinoma; TaqMan PCR

Indexed keywords

BIOLOGICAL MARKER; CD44V ANTIGEN; LGALS3 PROTEIN; METALLOTHIONEIN; PROTEIN BAX; PROTEIN KINASE LYN; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL STRUCTURE; CONTROLLED STUDY; GENE CLUSTER; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN VARIANT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID CARCINOMA;

ADENOCARCINOMA, FOLLICULAR; ADENOCARCINOMA, PAPILLARY; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; RNA, MESSENGER; TAQ POLYMERASE; THYROID NEOPLASMS; THYROIDECTOMY; TUMOR MARKERS, BIOLOGICAL;

EID: 33847756012     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-006-0348-5     Document Type: Article

References (47)

1. Amatschek S, Koenig U, Auer H, Steinlein P, Pacher M, Gruenfelder A, Dekan G, Vogl S, Kubista E, Heider KH, Stratowa C, Schreiber M, Sommergruber W (2004) Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. Cancer Res 264:844-856
2. Barden CB, Shister KW, Zhu B, Guiter G, Greenblatt DY, Zeiger MA, Fahey TJ 3rd (2003) Classification of follicular thyroid tumors by molecular signature: results of gene profiling. Clin Cancer Res 9:1792-1800
3. Benjamini Y, Yekutieli D (2001) The control of the false discovery rate in multiple testing under dependency. Ann Stat 29:1165-1188
4. Cai L, Wang GJ, Xu ZL, Deng DX, Chakrabarti S, Cherian MG (1998) Metallothionein and apoptosis in primary human hepatocellular carcinoma (HCC) from northern China. Anticancer Res 18:4667-4672
5. Castellone MD, Celetti A, Guarino V, Cirafici AM, Basolo F, Giannini R, Medico E, Kruhoffer M, Orntoft TF, Curcio F, Fusco A, Melillo RM, Santoro M (2004) Autocrine stimulation by osteopontin plays a pivotal role in the expression of the mitogenic and invasive phenotype of RET/PTC-transformed thyroid cells. Oncogene 23:2188-2196
6. Cerutti JM, Delcelo R, Amadei MJ, Nakabashi C, Maciel RM, Peterson B, Shoemaker J, Riggins GJ (2004) A preoperative diagnostic test that distinguishes benign from malignant thyroid carcinoma based on gene expression. J Clin Invest 113:1234-1242
7. Deng DX, Chakrabarti S, Waalkes MP, Cherian MG (1998) Metallothionein and apoptosis in primary human hepatocellular carcinoma and metastatic adenocarcinoma. Histopathology 32:340-347
8. Ding K, Lopez-Burks M, Sanchez-Duran JA, Korc M, Lander AD (2005) Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells. J Cell Biol 171:729-738
9. Finley DJ, Arora N, Zhu B, Gallagher L, Fahey TJ 3rd (2004) Molecular profiling distinguishes papillary carcinoma from benign thyroid nodules. J Clin Endocrinol Metab 89:3214-3223
10. Finley DJ, Zhu B, Barden CB, Fahey TJ 3rd (2004) Discrimination of benign and malignant thyroid nodules by molecular profiling. Ann Surg 240:425-436
11. Finn SP, Smyth P, O'Leary J, Sweeney EC, Sheils O (2003) Ret/PTC chimeric transcripts in an Irish cohort of sporadic papillary thyroid carcinoma. J Clin Endocrinol Metab 88:938-941
12. Fusco A, Grieco M, Santoro M, Berlingieri MT, Pilotti S, Pierotti MA, Della Porta G, Vecchio G (1987) A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature 328:170-172
13. Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, Pierotti MA, Della Porta G, Fusco A, Vecchio G (1990) PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60:557-563
14. Guarino V, Faviana P, Salvatore G, Castellone MD, Cirafici AM, De Falco V, Celetti A, Giannini R, Basolo F, Melillo RM, Santoro M (2005) Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness. J Clin Endocrinol Metab 90:5270-5278
15. Hermann S, Sturm I, Mrozek A, Klosterhalfen B, Hauptmann S, Dorken B, Daniel PT (2001) Bax expression in benign and malignant thyroid tumours: dysregulation of wild-type P53 is associated with a high Bax and P21 expression in thyroid carcinoma. Int J Cancer 92:805-811
16. Huang Y, Prasad M, Lemon WJ, Hampel H, Wright FA, Kornacker K, LiVolsi V, Frankel W, Kloos RT, Eng C, Pellegata NS, de la Chapelle A (2001) Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci USA 98:15044-15049
17. Huang Y, de la Chapelle A, Pellegata NS (2003) Hypermethylation, but not LOH, is associated with the low expression of MT1G and CRABP1 in papillary thyroid carcinoma. Int J Cancer 104:735-744
18. Hunt JL, Baloch ZW, Barnes L, Swalsky PA, Trusky CL, Sesatomi E, Finkelstein S, LiVolsi VA (2002) Loss of heterozygosity mutations of tumor suppressor genes in cytologically atypical areas in chronic lymphocytic thyroiditis. Endocr Pathol 13:321-330
19. Hwang ES, Kim DW, Hwang JH, Jung HS, Suh JM, Park YJ, Chung HK, Song JH, Park KC, Park SH, Yun HJ, Kim JM, Shong M (2004) Regulation of signal transducer and activator of transcription 1 (STAT1) and STAT1-dependent genes by RET/PTC (rearranged in transformation/papillary thyroid carcinoma) oncogenic tyrosine kinases. Mol Endocrinol 18:2672-2684
20. Jarzab B, Wiench M, Fujarewicz K, Simek K, Jarzab M, Oczko-Wojciechowska M, Wloch J, Czarniecka A, Chmielik E, Lange D, Pawlaczek A, Szpak S, Gubala E, Swierniak A (2005) Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications. Cancer Res 65:1587-1597
21. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454-1457
22. Lima J, Trovisco V, Soares P, Maximo V, Magalhaes J, Salvatore G, Santoro M, Bogdanova T, Tronko M, Abrosimov A, Jeremiah S, Thomas G, Williams D, Sobrinho-Simoes M (2004) BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. J Clin Endocrinol Metab 89:4267-4271
23. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(?Delta Delta C(T)) Method. Methods 25:402-408
24. Lloyd R, DeLellis R, Heitz P, Eng C (eds) (2004) Pathology and genetics of tumours of endocrine Organs. IARC Press
25. Lloyd RV, Erickson LA, Casey MB, Lam KY, Lohse CM, Asa SL, Chan JK, DeLellis RA, Harach HR, Kakudo K, LiVolsi VA, Rosai J, Sebo TJ, Sobrinho-Simoes M, Wenig BM, Lae ME (2004) Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma. Am J Surg Pathol 28:1336-1340
26. Marcos I, Borrego S, Antinolo G (2003) Molecular cloning and characterization of human RAB23, a member of the group of Rab GTPases. Int J Mol Med 12:983-987
27. Marsee DK, Vadysirisack DD, Morrison CD, Prasad ML, Eng C, Duh QY, Rauen KA, Kloos RT, Jhiang SM (2005) Variable expression of Coxsackie-adenovirus receptor in thyroid tumors: implications for adenoviral gene therapy. Thyroid 15:977-987
28. Mazzanti C, Zeiger MA, Costouros NG, Umbricht C, Westra WH, Smith D, Somervell H, Bevilacqua G, Alexander HR, Libutti SK (2004) Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res 64:2898-2903
29. Mitselou A, Vougiouklakis TG, Peschos D, Dallas P, Boumba VA, Agnantis NJ (2002) Immunohistochemical study of the expression of S-100 protein, epithelial membrane antigen, cytokeratin and carcinoembryonic antigen in thyroid lesions. Anticancer Res 22:1777-1780
30. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T, Yamashita S (2003) Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 88:4393-4397
31. Nartey N, Cherian MG, Banerjee D (1987) Immunohistochemical localization of metallothionein in human thyroid tumors. Am J Pathol 129:177-182
32. Nikiforova MN, Ciampi R, Salvatore G, Santoro M, Gandhi M, Knauf JA, Thomas GA, Jeremiah S, Bogdanova TI, Tronko MD, Fagin JA, Nikiforov YE (2004) Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Lett 209:1-6
33. Ofner D, Maier H, Riedmann B, Bammer T, Rumer A, Winde G, Bocker W, Jasani B, Schmid KW (1994) Immunohistochemical metallothionein expression in colorectal adenocarcinoma: correlation with tumour stage and patient survival. Virchows Arch 425:491-497
34. Rangel LB, Agarwal R, Sherman-Baust CA, Mello-Coelho V, Pizer ES, Ji H, Taub DD, Morin PJ (2004) Anomalous expression of the HLA-DR alpha and beta chains in ovarian and other cancers. Cancer Biol Ther 3:1021-1027
35. Santoro M, Carlomagno F, Hay ID, Herrmann MA, Grieco M, Melillo R, Pierotti MA, Bongarzone I, Della Porta G, Berger N, Peix JL, Paulin C, Fabien N, Vecchio G, Jenkins RB, Fusco A (1992) Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest 89:1517-1522
36. Schmid KW, Greeff M, Hittmair A, Totsch M, Ofner D, Dockhorn-Dworniczak B, Bocker W, Jasani B (1994) Metallothionein expression in normal, hyperplastic, and neoplastic thyroid follicular and parafollicular C cells using monoclonal antimetallothionein antibody E9. Endocr Pathol 5:114-122
37. Sheils OM, O'Leary JJ, Uhlmann V, Lattich K, Sweeney EC (2000) ret/PTC-1 activation in Hashimoto thyroiditis. Int J Surg Pathol 8:185-189
38. Sheils OM, Sweeney EC (1999) TSH receptor status of thyroid neoplasms-TaqMan RT-PCR analysis of archival material. J Pathol 188:87-92
39. Smyth P, Finn S, Cahill S, O'Regan E, Flavin R, O'Leary JJ, Sheils O (2005) ret/PTC and BRAF act as distinct molecular, time-dependant triggers in a sporadic Irish cohort of papillary thyroid carcinoma. Int J Surg Pathol 13:1-8
40. Stolf BS, Abreu CM, Mahler-Araujo MB, Dellamano M, Martins WK, de Carvalho MB, Curado MP, Diaz JP, Fabri A, Brentani H, Carvalho AF, Soares FA, Kowalski LP, Hirata R Jr, Reis LF (2005) Expression profile of malignant and non-malignant diseases of the thyroid gland reveals altered expression of a common set of genes in goiter and papillary carcinomas. Cancer Lett 227:59-73
41. Tanaka M, Adzuma K, Iwami M, Yoshimoto K, Monden Y, Itakura M (1995) Human calgizzarin; one colorectal cancer-related gene selected by a large scale random cDNA sequencing and Northern blot analysis. Cancer Lett 89:195-200
42. Thomas GA, Bunnell H, Cook HA, Williams ED, Nerovnya A, Cherstvoy ED, Tronko ND, Bogdanova TI, Chiappetta G, Viglietto G, Pentimalli F, Salvatore G, Fusco A, Santoro M, Vecchio G (1999) High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant. J Clin Endocrinol Metab 84:4232-4238
43. Turk B, Turk D, Turk V (2000) Lysosomal cysteine proteases: more than scavengers. Biochim Biophys Acta 1477:98-111
44. Villadangos JA, Bryant RA, Deussing J, Driessen C, Lennon-Dumenil AM, Riese RJ, Roth W, Saftig P, Shi GP, Chapman HA, Peters C, Ploegh HL (1999) Proteases involved in MHC class II antigen presentation. Immunol Rev 172:109-120
45. Williams ED (2000) Two proposals regarding the terminology of thyroid tumors. Int J Surg Pathol 8:181-183
46. Yano Y, Uematsu N, Yashiro T, Hara H, Ueno E, Miwa M, Tsujimoto G, Aiyoshi Y, Uchida K (2004) Gene expression profiling identifies platelet-derived growth factor as a diagnostic molecular marker for papillary thyroid carcinoma. Clin Cancer Res 10:2035-2043
47. Yu M, Xu M, Savas L, Khan A (1998) Discordant expression of Ii and HLA-DR in thyrocytes: a possible pathogenetic factor in Hashimoto's thyroiditis. Endocr Pathol 9:201-208